Evidence map›Paper›PMID 30402125›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2018

Protective Effects of Chinese Traditional Medicine Longhu Rendan against Atherosclerosis via Negative Regulation of LOX-1.

Sishan Yan, Teng Wu, Ning Li, Lingyi Zhang, Jun Song, Yunzheng Xu, Shumei Wang, Liqin Ding, Jiahua Jin, Ying Liu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. LOX-1: Regulation, Signaling and Its Role in Atherosclerosis.Antioxidants (Basel, Switzerland) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sishan YanGuangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
Teng WuKey Laboratory of Cardiovascular Disease and Department of Pathophysiology, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
Ning LiGuangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
Lingyi ZhangGuangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
Jun SongGuangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
Yunzheng XuGuangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
Shumei WangGuangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.
Liqin DingShanghai Zhonghua Pharmaceutical Co., Ltd., Shanghai 201707, China.
Jiahua JinShanghai Zhonghua Pharmaceutical Co., Ltd., Shanghai 201707, China.
Ying LiuGuangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.ORCID 0000-0003-1917-7263
Tian LanGuangdong Pharmaceutical University, Guangzhou, Guangdong 510006, China.ORCID 0000-0002-5783-6883

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Longhu Rendan (LHRD), a Chinese traditional compound medicine, has a remarkable treatment effect on motion sickness for about half a century. However, the role of LHRD in atherosclerosis treatment is still unclear. In this study, LHRD treatment significantly diminished total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels in apolipoprotein E gene-knockout (ApoE

Identifiers

PMID30402125
PMCPMC6196979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.